Apnimed's experimental drug reduced breathing interruptions by nearly 46.8% in clinical trials, offering a potential ...

The first oral pill for obstructive sleep apnea could be around the corner after company Apnimed reported positive results ...

The new pill, called AD109, is a combination of atomoxetine and aroxybutynin, two drugs that tell your brain to keep the ...

In today’s Health Alert, obstructive sleep apnea may soon be treated with a simple, once-a-day pill. This first-in-class oral ...

Once dismissed as just snoring, sleep apnea is now emerging as an early warning sign for serious conditions like Alzheimer’s, ...

Topline results from a second phase 3 trial of AD109-an investigational oral therapy combining aroxybutynin and ...

Apnimed has scored another phase 3 knockout. The Massachusetts biotech’s daily pill for obstructive sleep apnea reduced the ...

Moderate to severe OSA was associated with increased risk for severe and critical COVID-19, particularly in those with severe intermittent hypoxia.

Baron Funds, an investment management company, released its “Baron Discovery Fund” second-quarter 2025 investor letter. A ...

LunAIRo, Apnimed's second Phase 3 trial of AD109, met its primary endpoint, demonstrating a reduction in the Apnea-Hypopnea Index (AHI) f ...

(Reuters) - Eli Lilly's blockbuster diabetes drug Mounjaro and weight-loss therapy Zepbound, as well as Novo Nordisk's rival ...

University of Arizona Health Sciences researchers will take a precision medicine approach to treating obstructive sleep apnea in people with Down syndrome.